Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Am J Public Health. 2005 May;95(5):790-9.

    Passive immunization against poliomyelitis: the Hammon gamma globulin field trials, 1951-1953.

    Source

    Department of Infectious Diseases, University of Pittsburgh Graduate School of Public Health, School of Public Health, PA 15261, USA. rinaldo@pitt.edu

    Abstract

    Poliomyelitis has gone from being one of the worst scourges of the 20th century to nearing eradication in the 21st. This success is well known to be attributable to the Salk inactivated and Sabin attenuated poliovirus vaccines.However, before introduction of these vaccines, William McDowall Hammon of the University of Pittsburgh Graduate School of Public Health led the first major breakthrough in prevention of the disease by using passive immunization in one of the earliest double-blind, placebo-controlled clinical trials. This study provided the first evidence that antibodies to poliovirus could prevent the disease in humans.

    PMID:
    15855454
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC1449257
    Free PMC Article

    Images from this publication.See all images (4)Free text

    FIGURE 1—
    FIGURE 3—
    FIGURE 2—
    FIGURE 4—

      Supplemental Content

      Icon for Atypon Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk